



Allergan plc Board of Directors Statement on its Social Contract with Patients

The Board of Directors of Allergan is proud to support our Company's pursuit of medical innovation and commitment to patients. The Board has been supportive of this action from the beginning, and we are issuing this statement to underscore the strong connection between the Social Contract and the role it plays in the Corporate Governance of the Company.

Innovation in our industry requires a commitment to long-term investments in research and development to bring promising new medicines to market, and it has also proven to have profound societal impacts on life expectancy and health over the last generation. We believe it is our responsibility to price treatments in a way that makes them accessible and affordable to patients, while still encouraging future investment by providing return to our shareholders.

We have endorsed the four principles of Allergan's Social Contract with Patients:

- 1: Invest & Innovate**
- 2: Access & Price**
- 3: Quality & Safety**
- 4: Education**

Adhering to the principles of our Social Contract will be key to the Company's success, as it will enable us to fulfill our responsibilities to patients which, in turn, makes our business stronger and fuels our ability to generate return for our shareholders. Like all successful businesses, ours is built on trust from and with our customers and their patients. This Social Contract is a key component of that trust and it is imperative that our leaders focus on its tenets as we make business decisions that ultimately improve the health and well-being of patients.

Our Board's structure and composition lends itself to continuing thoughtful consideration of the four principles, as well as oversight of management's implementation of the Social Contract. By virtue of our current and prior work experience, and our participation on the boards of public and private entities, our Board members bring the perspective of all stakeholders to this discussion, including practicing physicians, private insurers, retail pharmacy, pharmacy benefit

managers, major healthcare systems, pharmaceutical companies and non-profit patient groups.

Our increasingly vibrant medical innovation ecosystem is discovering new medicines, improving outcomes for patients and, by doing so, lowering the overall cost of disease. It is a special privilege to work in this industry at this time of medical innovation. Allergan's Social Contract is good for our Company, and it is also vital for our most important constituents – the medical professionals and patients who count on Allergan to continue finding new treatments for their most pressing medical needs and the investors who expect us to create sustainable value as we serve our customers.